JP2013544493A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544493A5
JP2013544493A5 JP2013527360A JP2013527360A JP2013544493A5 JP 2013544493 A5 JP2013544493 A5 JP 2013544493A5 JP 2013527360 A JP2013527360 A JP 2013527360A JP 2013527360 A JP2013527360 A JP 2013527360A JP 2013544493 A5 JP2013544493 A5 JP 2013544493A5
Authority
JP
Japan
Prior art keywords
seq
residues
cdr
set forth
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013527360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544493A (ja
JP6327855B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/050439 external-priority patent/WO2012031273A2/en
Publication of JP2013544493A publication Critical patent/JP2013544493A/ja
Publication of JP2013544493A5 publication Critical patent/JP2013544493A5/ja
Application granted granted Critical
Publication of JP6327855B2 publication Critical patent/JP6327855B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013527360A 2010-09-03 2011-09-02 新規モジュレータ及びその使用法 Expired - Fee Related JP6327855B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38018110P 2010-09-03 2010-09-03
US61/380,181 2010-09-03
PCT/US2011/050439 WO2012031273A2 (en) 2010-09-03 2011-09-02 Novel modulators and methods of use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2016030715A Division JP2016094485A (ja) 2010-09-03 2016-02-22 新規モジュレータ及びその使用法
JP2018014408A Division JP2018115162A (ja) 2010-09-03 2018-01-31 新規モジュレータ及びその使用法

Publications (3)

Publication Number Publication Date
JP2013544493A JP2013544493A (ja) 2013-12-19
JP2013544493A5 true JP2013544493A5 (enExample) 2015-05-14
JP6327855B2 JP6327855B2 (ja) 2018-05-23

Family

ID=45771874

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013527360A Expired - Fee Related JP6327855B2 (ja) 2010-09-03 2011-09-02 新規モジュレータ及びその使用法
JP2016030715A Pending JP2016094485A (ja) 2010-09-03 2016-02-22 新規モジュレータ及びその使用法
JP2018014408A Pending JP2018115162A (ja) 2010-09-03 2018-01-31 新規モジュレータ及びその使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016030715A Pending JP2016094485A (ja) 2010-09-03 2016-02-22 新規モジュレータ及びその使用法
JP2018014408A Pending JP2018115162A (ja) 2010-09-03 2018-01-31 新規モジュレータ及びその使用法

Country Status (12)

Country Link
US (2) US9458231B2 (enExample)
EP (1) EP2611464B1 (enExample)
JP (3) JP6327855B2 (enExample)
KR (1) KR20140014064A (enExample)
CN (2) CN106620693A (enExample)
AU (2) AU2011295715B9 (enExample)
BR (1) BR112013005116A2 (enExample)
CA (1) CA2810016A1 (enExample)
IL (2) IL224969A (enExample)
NZ (1) NZ608814A (enExample)
SG (2) SG188328A1 (enExample)
WO (1) WO2012031273A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031273A2 (en) * 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
JP6454547B2 (ja) 2011-07-06 2019-01-16 ゲンマブ エー/エス 抗体重鎖のc末端の修飾による補体依存性細胞傷害の調節
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
ES2682345T3 (es) 2012-09-27 2018-09-20 Biocare Medical, Llc Sistemas y procedimientos de anticuerpos antiuroplaquina II
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
EP2962113B1 (en) 2013-02-28 2019-04-03 Biocare Medical, LLC Anti-p40 antibodies systems and methods
ES2765423T3 (es) 2013-10-03 2020-06-09 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti-SOX10
KR20160147855A (ko) * 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
KR102559731B1 (ko) * 2014-09-12 2023-07-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 대음세포작용 인간 항-cd46 항체 및 표적화된 암 치료제
RU2698205C2 (ru) 2014-12-18 2019-08-23 Ф. Хоффманн-Ля Рош Аг Способ определения антител, вызывающих комплемент-зависимую цитотоксичность
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
HK1257422A1 (zh) * 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
US10941204B2 (en) * 2015-10-30 2021-03-09 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4
CN109906381B (zh) * 2016-08-31 2023-03-31 新加坡科技研究局 鉴别、靶向以及分离人树突细胞(dc)前体“前dc”的方法及其用途
WO2018089829A1 (en) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
WO2018089807A2 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
EP3424305B1 (de) * 2017-07-04 2021-05-26 Andreas Stihl AG & Co. KG Verfahren zum assistieren beim fällen eines baums und system zum assistieren beim fällen eines baums
WO2019018538A1 (en) * 2017-07-20 2019-01-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. RECOMBINANT ANTIBODIES BINDING TO CD123
US11401329B2 (en) 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
PT3587445T (pt) * 2017-08-10 2024-03-14 Grifols Diagnostic Solutions Inc Um marcador de oligomerização compreendendo uma região fc de imunoglobulina e um domínio poli-his
CN107973854B (zh) * 2017-12-11 2021-05-04 苏州银河生物医药有限公司 Pdl1单克隆抗体及其应用
BR112020024223A2 (pt) 2018-05-30 2021-03-16 Abbvie Stemcentrx Llc Conjugados anticorpo fármaco anti-sez6 e métodos de uso
CN114555633A (zh) * 2019-06-26 2022-05-27 约翰霍普金斯大学 用于靶向扩增免疫效应细胞的方法和材料
CN114867493B (zh) * 2019-10-04 2026-04-10 阿尔伯特爱因斯坦医学院 Kir3dl3是免疫系统的抑制性受体及其用途
MX2022016197A (es) * 2020-06-18 2023-04-05 Bioatla Inc Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos.
AU2021320333A1 (en) 2020-08-07 2023-03-30 Fortis Therapeutics, Inc. Immunoconjugates targeting CD46 and methods of use thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス,インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
CN115873117B (zh) * 2022-11-11 2023-07-18 广州国家实验室 一种pd-l1单克隆抗体或其抗原结合片段及检测试剂盒

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2773702A (en) 1955-05-16 1956-12-11 William T Safko Jack-knifing preventing device for tractor-trailers
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5514787A (en) 1989-07-21 1996-05-07 Washington University DNA sequences encoding human membrane cofactor protein (MCP)
JP2750220B2 (ja) 1989-07-21 1998-05-13 ワシントン ユニバーシティ 組換え産生したヒト細胞膜補助因子タンパク(mcp)
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
WO1991005855A1 (en) 1989-10-12 1991-05-02 Imutran Limited Modified biological material
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5846715A (en) 1990-05-11 1998-12-08 The Austin Research Institute CD46 variants
EP0537171B1 (en) 1990-05-11 2002-09-18 The Austin Research Institute CD46 isoforms
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
JPH0445796A (ja) * 1990-06-08 1992-02-14 Kyowa Hakko Kogyo Co Ltd 抗mcpモノクローナル抗体
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
EP1413587A2 (en) 1991-05-03 2004-04-28 Washington University Modified complement system regulator
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
EP0749475A4 (en) 1992-08-26 1997-05-07 Harvard College USE OF CYTOKINE IP-10 AS ANTI-TUMOR AGENT
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
AUPM772494A0 (en) 1994-08-30 1994-09-22 Austin Research Institute, The Improvements in production of proteins in host cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
AUPN912396A0 (en) 1996-04-03 1996-05-02 St. Vincent's Hospital (Melbourne) Limited Complement mediated rejection of transfected tumour cells
WO1998034635A1 (en) 1997-02-07 1998-08-13 The Wistar Institute Methods and compositions for the inhibition of interleukin-12 production
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
ES2303358T3 (es) 1997-11-03 2008-08-01 Human Genome Sciences, Inc. Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral.
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6642009B2 (en) 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
EP1094110A1 (en) 1999-10-21 2001-04-25 Leadd B.V. Apoptosis inducing proteinaceous substance
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
WO2001088537A1 (en) 2000-05-12 2001-11-22 Martens Mark G Diagnostic method for screening complement regulatory protein levels
US20030129677A1 (en) 2000-05-12 2003-07-10 Martens Mark G. Diagnostic method for screening complement regulatory protein levels
EP1184458A1 (en) 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
US20020115065A1 (en) 2000-08-28 2002-08-22 Ton Logtenberg Differentially expressed epitopes and uses thereof
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002030954A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Method of purifying antibody
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン,エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
EP1441766B1 (en) 2001-10-16 2011-09-14 MacroGenics West, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
US20040126762A1 (en) 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
JP4472351B2 (ja) 2002-03-01 2010-06-02 イミューノメディクス、インコーポレイテッド インターナライジング抗cd74抗体およびその使用方法
CA2478239A1 (en) 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
WO2003093417A2 (en) 2002-05-01 2003-11-13 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation
US7906118B2 (en) 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
EP1507148B1 (en) 2003-08-25 2005-02-23 MTM Laboratories AG Method for detecting carcinomas in a solubilized cervical body sample
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
JP4874090B2 (ja) 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド 治療薬および診断薬を投与するための方法および組成物
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2004101756A2 (en) 2003-05-09 2004-11-25 Diadexus, Inc. Ovr110 antibody compositions and methods of use
EP1482052A1 (en) * 2003-05-27 2004-12-01 Cytos Biotechnology AG Modified polypeptides for targeting cell-entry of the adenoviruses of subtype B
EP1649038B1 (en) 2003-06-26 2014-07-02 Litron Laboratories Ltd. Method for the enumeration of micronucleated erythrocyte populations while distinguishing platelets and/or platelet-associated aggregates
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2574881C (en) 2004-08-04 2013-01-08 Amgen Inc. Antibodies to dkk-1
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
CN103073639A (zh) 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
CN101501187A (zh) 2006-06-06 2009-08-05 田纳西大学研究基金会 富含赘生干细胞的组合物及包含其的方法
WO2008007648A1 (fr) 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
US20100098632A1 (en) 2006-07-12 2010-04-22 Russell Stephen J Hydroxyapatite particles
US7763242B2 (en) 2006-09-07 2010-07-27 Scott and White Memorial Hospital Methods for treating myelodysplastic syndrome with a human interleukin-3-diphtheria toxin conjugate
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
EP1975239A1 (en) 2006-09-27 2008-10-01 Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening
EP2109668A4 (en) 2007-01-22 2011-10-05 Macrogenics West Inc HUMAN CANCER STEM CELLS
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
JP2010538012A (ja) 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド Igf−1rの複数のエピトープに結合する組成物
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
EP2242513A2 (en) 2008-01-18 2010-10-27 Hadasit Medical Research Services & Development Ltd. Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
EP2271364B1 (en) * 2008-04-10 2016-08-10 IBC Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
US8314213B2 (en) * 2008-04-18 2012-11-20 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
WO2010037134A2 (en) 2008-09-29 2010-04-01 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
US8753639B2 (en) 2009-03-31 2014-06-17 University Of Washington Through Its Center For Commercialization Compositions and methods for modulating the activity of complement regulatory proteins on target cells
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレート 改善された補体レセプター2(cr2)ターゲティング基
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
SG189212A1 (en) 2010-09-03 2013-05-31 Stem Centrx Inc Identification and enrichment of cell subpopulations
WO2012031273A2 (en) * 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
PE20160674A1 (es) 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
EP3209334A2 (en) 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Similar Documents

Publication Publication Date Title
CN113227135B (zh) 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
CN103260646B (zh) Notum蛋白调节剂和使用方法
JP6491701B2 (ja) 新規モジュレーターと使用の方法
KR102022734B1 (ko) 신규 조절제 및 용법
JP6327855B2 (ja) 新規モジュレータ及びその使用法
JP2018506981A (ja) 抗dll3キメラ抗原受容体および使用方法
KR20170010764A (ko) 신규한 항-rnf43 항체 및 사용 방법
KR20170085531A (ko) 항-cldn 키메라 항원 수용체 및 사용 방법
US9683032B2 (en) Anti-S100A4 antibody molecules and their uses
CA2759836A1 (en) Humanized axl antibodies
KR20160046914A (ko) 신규한 sez6 조절물질 및 사용방법
CN108623685A (zh) 抗ox40抗体及其用途
JP2020037571A (ja) Tmcc3の阻害による、癌を抑制するための方法
JP2015523852A5 (enExample)
JP2013533732A5 (enExample)
KR20170138465A (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
KR20240153397A (ko) 항 cd73 항체 및 이의 사용
HK40044653A (en) Novel modulators and methods of use
HK1191031A (en) Novel modulators and methods of use
HK1191031B (en) Novel modulators and methods of use